Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches

Methodologies for Investigating Drug Metabolism at the Early Drug Discovery Stage: Prediction of Hepatic Drug Clearance and P450 Contribution

(2011) Chie Emoto et al.   CURRENT DRUG METABOLISM

Characterization of Niflumic Acid as a Selective Inhibitor of Human Liver Microsomal UDP-Glucuronosyltransferase 1A9: Application to the Reaction Phenotyping of Acetaminophen Glucuronidation

(2011) J. O. Miners et al.   DRUG METABOLISM AND DISPOSITION

First-Pass Metabolism via UDP-Glucuronosyltransferase: a Barrier to Oral Bioavailability of Phenolics

(2011) Baojian Wu et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Regioselective Glucuronidation of Flavonols by Six Human UGT1A Isoforms

(2011) Baojian Wu et al.   PHARMACEUTICAL RESEARCH

Molecular Modeling of Cytochrome P450 and Drug Metabolism

(2010) Jing-Fang Wang et al.   CURRENT DRUG METABOLISM

How Many and Which Amino Acids Are Responsible for the Large Activity Differences between the Highly Homologous UDP-Glucuronosyltransferases (UGT) 1A9 and UGT1A10?

(2010) K. Itaaho et al.   DRUG METABOLISM AND DISPOSITION

Identification of the Position of Mono-O-glucuronide of Flavones and Flavonols by Analyzing Shift in Online UV Spectrum (λmax) Generated from an Online Diode Array Detector

(2010) Rashim Singh et al.   JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY

Ligand orientation governs conjugation capacity of UDP-glucuronosyltransferase 1A1

(2010) Yutaka Takaoka et al.   JOURNAL OF BIOCHEMISTRY

Three-Dimensional Quantitative Structure-Activity Relationship Studies on UGT1A9-Mediated 3-O-Glucuronidation of Natural Flavonols Using a Pharmacophore-Based Comparative Molecular Field Analysis Model

(2010) B. Wu et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

A Molecular Model of the Human UDP-Glucuronosyltransferase 1A1, Its Membrane Orientation, and the Interactions between Different Parts of the Enzyme

(2010) L. Laakkonen et al.   MOLECULAR PHARMACOLOGY

In silico and in vitro Approaches to Elucidate the Thermal Stability of Human UDP-glucuronosyltransferase (UGT) 1A9

(2009) Ryoichi Fujiwara et al.   Drug Metabolism and Pharmacokinetics

Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors

(2009) Philip Lazarus et al.   DRUG METABOLISM REVIEWS

The crystal structure of human UDP-glucuronosyltransferase 2B7 C-terminal end is the first mammalian UGT target to be revealed: the significance for human UGTs from both the 1A and 2B families

(2009) Anna Radominska-Pandya et al.   DRUG METABOLISM REVIEWS

The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping andin vitro–in vivoextrapolation of drug clearance and drug-drug interaction potential

(2009) John O. Miners et al.   DRUG METABOLISM REVIEWS

The Simcyp®Population-based ADME Simulator

(2009) Masoud Jamei et al.   Expert Opinion on Drug Metabolism & Toxicology

Structure and Concentration Changes Affect Characterization of UGT Isoform-Specific Metabolism of Isoflavones

(2009) Lan Tang et al.   MOLECULAR PHARMACEUTICS

Relative Importance of Intestinal and Hepatic Glucuronidation—Impact on the Prediction of Drug Clearance

(2009) Helen E. Cubitt et al.   PHARMACEUTICAL RESEARCH

Prediction of Drug Clearance by Glucuronidation from in Vitro Data: Use of Combined Cytochrome P450 and UDP-Glucuronosyltransferase Cofactors in Alamethicin-Activated Human Liver Microsomes

(2008) P. J. Kilford et al.   DRUG METABOLISM AND DISPOSITION

Mutation analysis in UGT1A9 suggests a relationship between substrate and catalytic residues in UDP-glucuronosyltransferases

(2008) A.-S. Patana et al.   PROTEIN ENGINEERING DESIGN & SELECTION